Comparative Pharmacology
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus KEFLET.
CEPHAPIRIN SODIUM vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
500 mg to 1 g IM or IV every 6 hours.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic